drugset / Trial / NCT00162214

Study of Dasatinib in Patients With Advanced Solid Tumors

NCT00162214

Phase 1 Terminated 60 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of Segment 1 of the study is to determine the effect of ketoconazole on dasatinib. The purpose of Segment 2 is to learn how dasatinib affects tumor growth in patients with advanced solid tumors.

Timeline

Start
2005-08
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketoconazole Small molecule 200 mg Oral
Comparator dasatinib anhydrous Small molecule 140 mg Oral

Indications